I wanted to put up a note to inform everyone that Manchester Pharmaceuticals has been acquired by Retrophin. As those who have been taking Chenodal know, Manchester has been manufacturing the medication for CTX patients in the US for about the past 2 years. Now that will shift to Retrophin. From their website, Retrophin is a biopharmaceutical company focused on the discovery, acquisition, development and commercialization of drugs for the treatment of debilitating and often life-threatening diseases for which there are currently limited patient options. I have had a few conversations with some of the individuals at Retrophin and have come away from those conversations excited for the future of care, advocacy, education, awareness, treatment, and research for CTX patients. I am eternally grateful for the work and contribution that Manchester and their staff provided as the manufacturers of Chenodal and credit them for having the confidence to hand over the future of CTX to Retrophin. Here is a link to the press release about the acquisition: http://amda-1pla2o.client.shareholder.com/releasedetail.cfm?ReleaseID=825424
Posted in Updates.